Sequence 40 from Patent US 20110319336

General Information


DRACP ID  DRACP01362

Peptide Name   Sequence 40 from Patent US 20110319336

Sequence  CTVALPGGYVRVC

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01362

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys1<--->Cys13

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C58H96N16O16S2

Absent amino acids  DEFHIKMNQSW

Common amino acids  V

Mass  155185

Pl  8.22

Basic residues  1

Acidic residues  0

Hydrophobic residues  5

Net charge  1

Boman Index  566

Hydrophobicity  110

Aliphatic Index  104.62

Half Life 
  Mammalian: 1.2 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  1615

Absorbance 280nm  134.58

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2011/0319336 A1

Patent Title  Selective anticancer chimeric peptide.

Other Iinformation  Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013

Other Published ID  CN102238965A  EP2370107A2  WO2010064207A2  WO2010064207A3 




DRACP is developed by Dr.Zheng's team.